Literature DB >> 12636147

Timing and completeness of routine testing for antibodies to human immunodeficiency virus type 1 among active duty members of the U.S. Armed Forces.

Michael J Silverberg1, John F Brundage, Mark V Rubertone.   

Abstract

Since 1985, the U.S. Armed Forces have conducted routine testing of personnel for antibodies to human immunodeficiency virus type 1. Sera that remain after testing are archived in the Department of Defense serum repository for potential uses in medical surveillance, clinical, and research activities. The goal of this study was to document the timing and completeness of routine human immunodeficiency virus type 1 testing among active duty military personnel and to identify factors associated with more recent testing. Demographic characteristics for active duty personnel were obtained from the Defense Medical Surveillance System. Of all individuals on active duty on August 31, 2001 (N = 1,370,367), 98.6% had been tested. Older personnel, those with postgraduate degrees, and married personnel had the longest time intervals since their most recent tests. The results of this analysis may inform the planning and conduct of human immunodeficiency virus type 1 prevention programs as well as deployment-related or other surveillance activities.

Entities:  

Mesh:

Year:  2003        PMID: 12636147

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  2 in total

1.  Insight into infection-mediated prostate damage: Contrasting patterns of C-reactive protein and prostate-specific antigen levels during infection.

Authors:  Melissa Milbrandt; Anke C Winter; Remington L Nevin; Ratna Pakpahan; Gary Bradwin; Angelo M De Marzo; Debra J Elliott; Charlotte A Gaydos; William B Isaacs; William G Nelson; Nader Rifai; Lori J Sokoll; Jonathan M Zenilman; Elizabeth A Platz; Siobhan Sutcliffe
Journal:  Prostate       Date:  2017-07-12       Impact factor: 4.104

2.  Prostate involvement during sexually transmitted infections as measured by prostate-specific antigen concentration.

Authors:  S Sutcliffe; R L Nevin; R Pakpahan; D J Elliott; S R Cole; A M De Marzo; C A Gaydos; W B Isaacs; W G Nelson; L J Sokoll; J M Zenilman; S B Cersovsky; E A Platz
Journal:  Br J Cancer       Date:  2011-07-26       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.